Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1979 1
1980 1
1986 1
1987 1
1988 2
1989 3
1991 2
1993 2
1994 1
1995 1
1999 2
2000 5
2001 4
2002 6
2003 8
2004 4
2005 6
2006 6
2007 11
2008 11
2009 5
2010 4
2011 7
2012 16
2013 10
2014 11
2015 9
2016 9
2017 20
2018 6
2019 10
2020 10
2021 5
2022 6
2023 13
2024 10
2025 12
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.
Sulaica E, Han T, Wang W, Bhat R, Trivedi MV, Niravath P. Sulaica E, et al. Breast Cancer Res Treat. 2016 Jun;157(2):203-210. doi: 10.1007/s10549-016-3827-7. Epub 2016 May 13. Breast Cancer Res Treat. 2016. PMID: 27178335 Review.
Atrophic vaginitis represents a major barrier to compliance with aromatase inhibitor (AI) therapy in breast cancer (BC) survivors. ...This makes it difficult to evaluate even indirectly the potential risk of BC recurrence with vaginal estrogen t …
Atrophic vaginitis represents a major barrier to compliance with aromatase inhibitor (AI) therapy in breast cancer (BC) …
Management of genitourinary syndrome of menopause in breast cancer survivors: An update.
Lubián López DM. Lubián López DM. World J Clin Oncol. 2022 Feb 24;13(2):71-100. doi: 10.5306/wjco.v13.i2.71. World J Clin Oncol. 2022. PMID: 35316932 Free PMC article. Review.
Women receiving antiestrogen therapy, specifically aromatase inhibitors, often suffer from vaginal dryness, itching, irritation, dyspareunia, and dysuria, collectively known as genitourinary syndrome of menopause (GSM), that it can in turn lead to pain, disco …
Women receiving antiestrogen therapy, specifically aromatase inhibitors, often suffer from vaginal dryness, itching, ir …
Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.
Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Cold S, et al. J Natl Cancer Inst. 2022 Oct 6;114(10):1347-1354. doi: 10.1093/jnci/djac112. J Natl Cancer Inst. 2022. PMID: 35854422 Free PMC article.
The adjusted relative risk of recurrence was 1.08 (95% confidence interval [CI] = 0.89 to 1.32) for VET (1.39 [95% CI = 1.04 to 1.85 in the subgroup receiving adjuvant aromatase inhibitors]) and 1.05 (95% CI = 0.62 to 1.78) for MHT. The adjusted hazard ratios for ov …
The adjusted relative risk of recurrence was 1.08 (95% confidence interval [CI] = 0.89 to 1.32) for VET (1.39 [95% CI = 1.04 to 1.85 in the …
Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.
Moegele M, Buchholz S, Seitz S, Ortmann O. Moegele M, et al. Arch Gynecol Obstet. 2012 May;285(5):1397-402. doi: 10.1007/s00404-011-2181-6. Epub 2012 Jan 3. Arch Gynecol Obstet. 2012. PMID: 22212649 Review.
About 50% of postmenopausal women between 50 and 60 years and 72% of women over 70 years suffer from vulvovaginal athrophy (VVA). Adjuvant treatment with aromatase inhibitors (AIs) improves outcomes in postmenopausal women with hormone receptor positive early stage …
About 50% of postmenopausal women between 50 and 60 years and 72% of women over 70 years suffer from vulvovaginal athrophy (VVA). Adjuvant t …
Vaginal Testosterone for Management of Aromatase Inhibitor-Related Sexual Dysfunction: An Integrative Review.
Lemke EA, Madsen LT, Dains JE. Lemke EA, et al. Oncol Nurs Forum. 2017 May 1;44(3):296-301. doi: 10.1188/17.ONF.296-301. Oncol Nurs Forum. 2017. PMID: 28635978
PROBLEM IDENTIFICATION: Women taking aromatase inhibitors (AIs) as part of the management of hormone receptor-positive breast cancer experience more symptoms of sexual dysfunction, including vaginal atrophy, as opposed to postmenopausal women and women treate …
PROBLEM IDENTIFICATION: Women taking aromatase inhibitors (AIs) as part of the management of hormone receptor-positive breast …
Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial.
Faltinová M, Vehmanen L, Lyytinen H, Savolainen-Peltonen H, Virtanen A, Haanpää M, Hämäläinen E, Tiitinen A, Mattson J. Faltinová M, et al. Breast Cancer Res Treat. 2025 Apr;210(2):295-305. doi: 10.1007/s10549-024-07564-8. Epub 2024 Dec 27. Breast Cancer Res Treat. 2025. PMID: 39729211 Free PMC article.
Serum E2 variations were shown by using both LC-MS/MS methods. Vaginal pH, vaginal maturation index (VMI), and VVA symptoms significantly improved during treatment. ...Highly sensitive LC-MS/MS is a promising method for monitoring E2 levels during aromatase …
Serum E2 variations were shown by using both LC-MS/MS methods. Vaginal pH, vaginal maturation index (VMI), and VVA symptoms si …
Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ. Burstein HJ. Breast. 2007 Jun;16(3):223-34. doi: 10.1016/j.breast.2007.01.011. Epub 2007 Mar 21. Breast. 2007. PMID: 17368903 Review.
Aromatase inhibitors (AIs) are widely used as an adjuvant endocrine treatment in postmenopausal women with early-stage breast cancer. ...By contrast, the low levels of estrogen achieved with aromatase inhibition contribute to menopausal symptoms, va …
Aromatase inhibitors (AIs) are widely used as an adjuvant endocrine treatment in postmenopausal women with early-stage breast …
Therapeutic Choices for Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors: A Systematic Review and Update.
Merlino L, D'Ovidio G, Matys V, Piccioni MG, Porpora MG, Senatori R, Viscardi MF, Vitale A, Della Rocca C, On Behalf Of Policlinico Umberto I Collaborators. Merlino L, et al. Pharmaceuticals (Basel). 2023 Apr 6;16(4):550. doi: 10.3390/ph16040550. Pharmaceuticals (Basel). 2023. PMID: 37111307 Free PMC article. Review.
This is a complication that often can occur as a result of breast cancer treatment, causing symptoms such as vaginal dryness, itching, burning, dyspareunia, dysuria, pain, discomfort, and impairment of sexual function. ...We reviewed systemic hormone therapy, local hormone …
This is a complication that often can occur as a result of breast cancer treatment, causing symptoms such as vaginal dryness, itching …
Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
Pérez-López FR, Phillips N, Vieira-Baptista P, Cohen-Sacher B, Fialho SCAV, Stockdale CK. Pérez-López FR, et al. Gynecol Endocrinol. 2021 Aug;37(8):746-752. doi: 10.1080/09513590.2021.1943346. Epub 2021 Jun 25. Gynecol Endocrinol. 2021. PMID: 34169794 Review.
Beneficial options include lubricants, moisturizers, vaginal estrogens (estradiol, estriol, promestriene, conjugated estrogens), androgens, prasterone, and laser application. ...However, limited absorption of low/ultra-low doses of estrogens suggests s …
Beneficial options include lubricants, moisturizers, vaginal estrogens (estradiol, estriol, promestriene, conjugated estrog …
The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis.
Pavlović RT, Janković SM, Milovanović JR, Stefanović SM, Folić MM, Milovanović OZ, Mamillapalli C, Milosavljević MN. Pavlović RT, et al. Clin Breast Cancer. 2019 Dec;19(6):e731-e740. doi: 10.1016/j.clbc.2019.07.007. Epub 2019 Aug 21. Clin Breast Cancer. 2019. PMID: 31522958
Atrophic vaginitis is a relatively common adverse effect of aromatase inhibitors used as an adjunctive treatment for breast cancer. ...The safety of local hormonal therapy of vaginal atrophy in women on aromatase inhibitors were summarize …
Atrophic vaginitis is a relatively common adverse effect of aromatase inhibitors used as an adjunctive treatment for br …
228 results